Therapeutic Effects of Rituximab on Burkitt Lymphoma in Children and Adolescents
DOI:
https://doi.org/10.61173/py9egk98Keywords:
Rituximab, Burkitt lymphoma, children, adolescentsAbstract
Burkitt lymphoma (BL) is a rapidly advancing B-cell non-Hodgkin lymphoma. It is also one of the fastest-growing human cancers. The peak age of onset is around ten years old. Children with BL are generally more likely to recover or survive without serious long-term effects. More than 90 percent of children and adolescents can be cured by receiving higher doses of chemotherapy drugs and more frequent treatments. Existing research mainly studies the optimization of treatment strategies and the exploration of new therapies, including chemotherapy, targeted therapy, immunotherapy, etc. There is also research on molecular biology, genetics, and tumor immune microenvironment, as well as factors related to patient prognosis. However, there are specific constraints related to the mechanism of drug resistance and the quality of life for individuals with BL. Rituximab is a cancer treatment approved for patients, functioning as an anti-CD20 antibody. The application of Rituximab on BL with traditional chemotherapy increased the cure rate, especially in patients with Central nervous system (CNS) lesions or refractory BL patients. This review aims to summarize the working mechanism of rituximab, the overall therapeutic effect of rituximab in patients with BL, especially children, the treatment of CNS involved in BL, the impact of rituximab on relapse rates, and the shortcomings of rituximab.
References
[1] Roschewski M, Staudt LM, Wilson WH. Burkitt’s lymphoma. The New England journal of medicine, 2022, 387(12): 1111- 1122.
[2] Ahsanuddin S, Cadwell JB, Sangal NR, Grube JG, Fang CH, Baredes S, Eloy JA. Survival predictors of head and neck Burkitt’s lymphoma: an analysis of the SEER database. Otolaryngology--head and neck surgery, 2022, 167(1): 79-88.
[3] Kalisz K, Alessandrino F, Beck R, Smith D, Kikano E, Ramaiya NH, Tirumani SH. An update on Burkitt lymphoma: a review of pathogenesis and multimodality imaging assessment of disease presentation, treatment response, and recurrence. Insights Imaging, 2019, 10(1): 56.
[4] Singh A, Obiorah IE. Aggressive non-Hodgkin lymphoma in the pediatric and young adult population; diagnostic and molecular pearls of wisdom. Seminars in Diagnostic Pathology, 2023, 40(6): 392-400.
[5] Okebe JU, Skoetz N, Meremikwu MM, Richards S. Therapeutic interventions for Burkitt lymphoma in children. Cochrane Database of Systematic Reviews, 2011, 2011(7): CD005198.
[6] Borker A, Choudhary N. Rituximab. Indian Pediatr, 2011, 48(8): 627-32.
[7] Miles RR, Arnold S, Cairo MS. Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia. British journal of haematology, 2012, 156(6): 730-43.
[8] Pierpont TM, Limper CB, Richards KL. Past, Present, and Future of Rituximab-The World’s First Oncology Monoclonal Antibody Therapy. Frontiers in Oncology, 2018, 4;8:163.
[9] Borker A, Choudhary N. Rituximab. Indian Pediatr, 2011, 48(8): 627-32.
[10] Nie M, Wang Y, Bi XW, Xia Y, Sun P, Liu PP, Li ZM, Jiang WQ. Effect of rituximab on adult Burkitt’s lymphoma: a systematic review and meta-analysis. Annals of hematology, 2016, 95 (1):19-26.
[11] Barnes JA, Lacasce AS, Feng Y, Toomey CE, Neuberg D, Michaelson JS, Hochberg EP, Abramson JS. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt’s lymphoma: a retrospective analysis. Annals of hematology, 2011, 22(8):1859-64.
[12] Nagpal S, Glantz MJ, Recht L. Treatment and prevention of secondary CNS lymphoma. Seminars in Neurology, 2010, 30(3):263-72.
[13] Goldman S, Smith L, Galardy P, Perkins SL, Frazer JK, Sanger W, Anderson JR, Gross TG, Weinstein H, Harrison L, Shiramizu B, Barth M, Cairo MS. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children’s Oncology Group Report. British journal of haematology, 2014, 167(3):394-401.
[14] Goldman S, Smith L, Galardy P, Perkins SL, Frazer JK, Sanger W, Anderson JR, Gross TG, Weinstein H, Harrison L, Shiramizu B, Barth M, Cairo MS. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children’s Oncology Group Report. British journal of haematology, 2014, 167(3): 394-401.
[15] Moleti ML, Testi AM, Foà R. Treatment of relapsed/ refractory paediatric aggressive B-cell non-Hodgkin lymphoma. British journal of haematology, 2020, 189(5): 826-843.
[16] Akbayram S, Doğan M, Akgün C, Erbey F, Caksen H, Oner AF. Use of rituximab in three children with relapsed/refractory Burkitt lymphoma. Targeted oncology, 2010, 5(4): 291-4.
[17] Umeda K, Fujino H, Saida S, Kato I, Hiramatsu H, Yamada T, Hori T, Adachi S, Heike T, Watanabe K. Rituximab-combination chemotherapy achieves a 10th cycle of remission for Burkitt’s lymphoma. Pediatrics International, 2015, 57(2): e30-3.
[18] Hagberg H, Holmbom E. Risk factors for side effects during first infusion of rituximab-definition of a low risk group. Medical oncologists, 2000, 17(3): 218-21.
[19] Öztürk E, Özyiğit LP, Öztürk AB, Akay MO, Çetiner M, Ferhanoğlu B. Rituximab desensitization in three patients with severe rituximab allergy. Current Problems in Cancer, 2017, 41(5):349-354.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
